EDMONTON, Alberta, Jan. 31, 2012 (GLOBE NEWSWIRE) -- Consistent with prior communications from ILJIN, the company is pursuing discussions with ILJIN Life Science Co., Ltd. (“ILJIN”) to potentially change the current relationship with ILJIN in order to better advance the voclosporin program. The company has therefore chosen to exercise its right to terminate the existing Development, Distribution and License Agreement (the “DDL”) with ILJIN. In doing so, Isotechnika secures full rights to voclosporin for transplant and autoimmune indications in the United States and other regions outside of Canada, Israel, South Africa, China, Taiwan and Hong Kong. The company already owns full rights in Europe.
